To ensure that the antitumor activity of UCART7 is preserved in the setting of CD7-KO HSCs, we proceeded to add CCRF-CEM, a CD7+ T-ALL cell line, to the HSC-engrafted mice prior to UCART7 injection (Figure 6A). The gene discussed is CD7; the disease is acute lymphoblastic leukemia.